Effector Therapeutics Stock Net Income
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Effector Therapeutics fundamentals help investors to digest information that contributes to Effector Therapeutics' financial success or failures. It also enables traders to predict the movement of Effector Stock. The fundamental analysis module provides a way to measure Effector Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Effector Therapeutics stock.
Effector |
Effector Therapeutics Company Net Income Analysis
Effector Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Effector Therapeutics Net Income | (35.81 M) |
Most of Effector Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Effector Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Effector Therapeutics reported net income of (35.81 Million). This is 110.49% lower than that of the Biotechnology sector and 151.13% lower than that of the Health Care industry. The net income for all United States stocks is 106.27% higher than that of the company.
Effector Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Effector Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Effector Therapeutics could also be used in its relative valuation, which is a method of valuing Effector Therapeutics by comparing valuation metrics of similar companies.Effector Therapeutics is currently under evaluation in net income category among its peers.
Effector Fundamentals
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 23.71 % | ||||
| Number Of Shares Shorted | 91.62 K | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X | ||||
| Gross Profit | (19.76 M) | ||||
| EBITDA | (33.73 M) | ||||
| Net Income | (35.81 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 19.45 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | (12.57) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 846.79 K | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
| Working Capital | (5.96 M) | ||||
| Net Asset | 20.54 M |
About Effector Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Effector Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Effector Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Effector Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Effector Stock
Moving against Effector Stock
| 0.39 | VERA | Vera Therapeutics | PairCorr |
| 0.33 | VCYT | Veracyte | PairCorr |
| 0.32 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.32 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |